Perfil dos custos ambulatoriais no tratamento de neoplasia prostática

Abstract

Prostate cancer (CaP) is the most common cancer among men and the second type that most progresses to death in these patients. Health expenditures can represent an important portion of government investments, especially in countries where the health system is universal. The research aimed to estimate the direct medical costs of prostate cancer care in the outpatient setting of the Unified Health System, between 2009 and 2018. This is a descriptive, retrospective study, with a ten-year time horizon. A partial economic analysis was carried out in order to verify the direct medical costs in the treatment of prostate cancer in a pole city in the macro-southeast of Minas Gerais. The selection of medical records was based on the International Code of Diseases (ICD), the ICD-10, and the data through the Information Technology Department of the Unified Health System (DATASUS). 94,001 procedures were selected, from which they were performed in 2,303 patients during the study period, with a mean of 38.7 ± 43.01 (mean ± standard deviation) procedures per patient. The average age ranged from 60 to 97 years. In relation to ethnicity, 36.97% white, 9.74% black, 6.05% brown, the distribution of assistance was 32.4% in ASCOMCER; 19.7% at the Dr. João Felício Hospital and 47.8% at the Oncological Institute. 94001 procedures were paid by SUS at a total cost of R$35,858,257.15. The mean cost per procedure was R$381.47 ± R$472.28 (mean ± standard deviation). The evidence identified in this research can be used to inform the planning of clinical services, budgets and contribute to the promotion of future research on health economic evaluations.